The total European orthobiologics market is growing at a rate of 1.6%, which will take the 2018 market value of €521.2 million up to €582.3 million by 2025. Constraints on reimbursements will continue to limit the European orthobiologics market. Presently, only a few premium products under the umbrella of pharmaceuticals are reimbursed by the government
Overall, the U.S. Orthopedic Biomaterials market was valued at $3.7 billion in 2021. This is expected to increase over the forecast period at a CAGR of 3.6% to reach $4.7 billion. Demographic factors in the U.S. continue to be the largest driver within the orthopedic biomaterials market. This is primarily due to the growing elderly
Industry Trends A particular trend in the U.S. orthobiologics market is competitors that are seeking to penetrate high growth segments outside their traditional space by distributing existing products manufactured by other companies, rather than creating their own. This often involves partnering with a company by taking on the costs associated with regulation and market approval,
Bone is a biologically active tissue and will regenerate whenever possible; however, there are instances where the damage is significant enough to warrant a scaffold to help rejoin the fissure or cavity. Bone grafting is a surgical procedure in which damaged bone is replaced with autograft tissue, allograft tissue or a bone graft substitute, which can be either synthetic or metal.
During an autograft procedure, tissue is harvested from the patients iliac crest, or possibly the distal femur or proximal tibia, and placed at the injury site. An allograft procedure uses donated cadaveric tissue. A grafting procedure using a bone graft substitute replaces human tissue with a synthetic or metal material. For the purposes of this report, metal replacement materials will be excluded, as they are not considered biomaterials.